Currently predicting for Thu, 4 Jun 2026

GERN Prediction Chart

GERN Predictions History

Latest community submissions for GERN.
Predictor Target Session Target Price Result Direction Accuracy Score
May 6, 2019 $1.82 +1.21% $1.80 X 98.79% 1
May 3, 2019 $1.88 +4.44% $1.80 X 95.56% 0
Apr 30, 2019 $1.93 +6.04% $1.82 X 93.96% 0
Apr 24, 2019 $1.85 -1.07% $1.87 X 98.93% 1
Apr 23, 2019 $2.03 +5.73% $1.92 X 94.27% 0
JS JS Pro
Nov 5, 2018 $1.55 -12.43% $1.77 X 87.60% 0
Nov 5, 2018 $4.93 +178.53% Unrealistic Excluded from avg $1.77 X 0.00% 0
Nov 5, 2018 $1.87 +5.65% $1.77 X 94.40% 0
Ace Ace
Nov 5, 2018 $1.91 +7.91% $1.77 X 92.10% 0
Nov 5, 2018 $2.58 +45.76% $1.77 X 54.20% 0
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for GERN with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT GERON CORPORATION
Geron
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes a...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE